Modulation of human monocyte CD36 by type 2 diabetes mellitus and other atherosclerotic risk factors.

@article{BernalLopez2011ModulationOH,
  title={Modulation of human monocyte CD36 by type 2 diabetes mellitus and other atherosclerotic risk factors.},
  author={Rosa M Bernal-Lopez and Vicenta Llorente-Cort{\'e}s and Dolores L{\'o}pez-Carmona and Dolores M Mayas and Ricardo G{\'o}mez-Huelgas and Francisco J Tinahones and Lina Badimon},
  journal={European journal of clinical investigation},
  year={2011},
  volume={41 8},
  pages={854-62}
}
BACKGROUND The pathophysiological role of CD36 in atherosclerosis seems to be largely dependent on its pro-inflammatory function and ability to take up oxidized low-density lipoprotein. Controversy exists concerning the potential beneficial/harmful effects of vascular CD36 inhibition in atherosclerosis. However, as atherosclerosis in murine models does not result in clinical end points such as plaque rupture and thrombotic ischaemia, typical of human disease, clinical studies are required to… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS